Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Midpeliq reduces glucose load.

Noritomo Itami1, Yaushige Tsuji, Yoshio Katsuki

  • 1Nikko Memorial Hospital, Hokkaido, Japan.

Advances in Peritoneal Dialysis. Conference on Peritoneal Dialysis
|February 7, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preserved seasonal variation in glycemic control in patients with type 2 diabetes mellitus during COVID-19: a 3-year-long retrospective cohort study in older adults in Japan.

BMC endocrine disorders·2024
Same author

Anti-pruritic effect of nemolizumab in hemodialysis patients with uremic pruritus: a phase II, randomized, double-blind, placebo-controlled clinical study.

Clinical and experimental nephrology·2021
Same author

Prasugrel effectively reduces the platelet reactivity units in patients with genetically metabolic dysfunction of cytochrome P450 2C19 who are treated with long-term dual antiplatelet therapy after undergoing drug-eluting stent implantation.

Heart and vessels·2019
Same author

A Clinical Significance of Intermittent Infusion Hemodiafiltration Using Backfiltration of Ultrapure Dialysis Fluid Compared to Hemodialysis: A Multicenter Randomized Controlled Crossover Trial.

Blood purification·2019
Same author

Dialysis therapy: Its past, present, and future? My personal recollection of dialysis therapy.

The journal of vascular access·2019
Same author

Effect of Oral Alfacalcidol on Clinical Outcomes in Patients Without Secondary Hyperparathyroidism Receiving Maintenance Hemodialysis: The J-DAVID Randomized Clinical Trial.

JAMA·2018

New neutral-pH peritoneal dialysis (PD) solutions like Midpeliq may improve patient outcomes by allowing the use of lower glucose concentrations. This could reduce glucose load and toxic effects in PD patients experiencing ultrafiltration failure.

Area of Science:

  • Nephrology
  • Biomaterials Science

Background:

  • High rates of technique failure in peritoneal dialysis (PD) in Japan are linked to ultrafiltration failure, potentially caused by bioincompatible acidic PD solutions.
  • Conventional acidic PD solutions have been associated with ultrafiltration failure in long-term PD patients.

Observation:

  • A neutral-pH, lactate-buffered PD solution with low glucose degradation products (GDPs), Midpeliq, was introduced in Japan in 2001.
  • Three patients were switched from conventional acidic PD solutions to Midpeliq.
  • Two of these patients were subsequently able to use lower-glucose PD solutions.

Findings:

  • Case 1: A patient switched to Midpeliq experienced increased fluid removal and reduced PD exchange frequency, enabling use of a lower glucose concentration (1.35%).
  • Case 2: A patient switched to Midpeliq showed increased daily drainage volume and transitioned to a lower glucose concentration (1.35%) PD solution.

Related Experiment Videos

  • These observations suggest Midpeliq may facilitate reduced glucose load and fewer peritoneal toxic effects.

    • Implications:

    • Neutral-pH PD solutions may offer an alternative for patients suffering from ultrafiltration failure.
    • Midpeliq demonstrates potential in reducing glucose load and improving PD patient management.
    • Further research into neutral-pH PD solutions could lead to improved PD therapy and reduced technique failure rates.